# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
The Company recommends that shareholders review the recent report from proxy advisor Glass Lewis, which recommends shareholders...
The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin...
Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Per...
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate ...